Alternative Data for Longeveron
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Instagram Followers | 433 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 7 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 12,814 | Sign up | Sign up | Sign up |
| X Followers | 375 | Sign up | Sign up | Sign up |
| X Mentions | 8 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 39 | Sign up | Sign up | Sign up |
About Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan.
| Price | $0.89 |
| Target Price | Sign up |
| Volume | 243,386 |
| Market Cap | $15M |
| Year Range | $0.48 - $1.74 |
| Dividend Yield | 0% |
| PE Ratio | 2.95 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem CellFebruary 25 - GlobeNewswire |
|
Longeveron Appoints Stephen H. Willard CEO, Effective Feb. 11, Succeeding Than PowellFebruary 13 - Benzinga |
|
 |
Which stocks are moving on Tuesday?March 10 - ChartMill |
 |
Curious about the most active stocks on Tuesday?March 10 - ChartMill |
|
Let's have a look at the top gainers and losers in the middle of the day of today's session.March 10 - ChartMill |
 |
Gapping stocks in Tuesday's sessionMarch 10 - ChartMill |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 140,000 | 12,000 | 130,000 | -7.2M | -7M | -0.390 |
| Q2 '25 | 320,000 | 170,000 | 150,000 | -5M | -4.8M | -0.330 |
| Q1 '25 | 380,000 | 110,000 | 280,000 | -5M | -4.8M | -0.340 |
| Q4 '24 | 600,000 | 73,000 | 530,000 | -4.1M | -4M | -0.270 |
| Q3 '24 | 770,000 | 91,000 | 680,000 | -4.4M | -4.4M | -0.340 |
Insider Transactions View All
| Baluch Khoso filed to buy 52,516 shares at $0. August 13 '25 |
| Baluch Khoso filed to buy 29,415 shares at $0. August 13 '25 |
| Locklear Lisa filed to buy 250,964 shares at $0. August 13 '25 |
| Locklear Lisa filed to buy 29,415 shares at $0. August 13 '25 |
| Soffer Rock filed to sell 209,034 shares at $1.3. June 2 '25 |
Similar companies
Read more about Longeveron (LGVN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Longeveron
The Market Cap of Longeveron is $15M.
As of today, Longeveron's PE (Price to Earnings) ratio is 2.95.
Currently, the price of one share of Longeveron stock is $0.89.
The LGVN stock price chart above provides a comprehensive visual representation of Longeveron's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Longeveron shares. Our platform offers an up-to-date LGVN stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Longeveron (LGVN) does not offer dividends to its shareholders. Investors interested in Longeveron should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Longeveron are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
